New treatment options for metastatic renal cell carcinoma.
New treatment options for metastatic renal cell carcinoma.
复制标题
DOI：
10.1136/esmoopen-2017-000185
复制
发表时间：
2017
期刊：
影响因子：
7.3
通讯作者：
Strijbos MH
中科院分区：
文献类型：
--
作者：
Rodriguez-Vida A;Hutson TE;Bellmunt J;Strijbos MH
在过去的十年中，随着抗血管生成药物和酪氨酸激酶抑制剂的出现，晚期或转移性肾细胞癌 (RCC) 的治疗发生了革命性的变化。此后，几种靶向血管内皮生长因子（VEGF）途径（舒尼替尼、贝伐珠单抗、帕唑帕尼、阿西替尼）或雷帕霉素途径哺乳动物靶点（替西罗莫司、依维莫司）的药物逐渐被批准用于晚期肾细胞癌患者的一线或后期治疗，并成为新的治疗标准。结果，晚期 RCC 患者的生存期显着改善，从细胞因子时代约 12 个月的中位总生存期提高到一线 VEGF 抑制剂的超过 26 个月。近两年来，随着免疫检查点抑制剂，特别是针对程序性细胞死亡-1受体的药物的出现，以及新一代酪氨酸激酶受体抑制剂的出现，晚期肾细胞癌的治疗经历了第二次革命。本文将回顾可用于治疗晚期肾细胞癌的新治疗方案，以及目前正在研究的未来潜在分子靶点。
During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then progressively approved for first-line or later-line use in the treatment of patients with advanced RCC and became the new standard of care. As a result, the survival of patients with advanced RCC has significantly improved from a median overall survival of approximately 12 months in the cytokines era to more than 26 months with first-line VEGF inhibitors. During the two last years, the treatment of advanced RCC has witnessed a second revolution with the advent of immune checkpoint inhibitors, especially agents targeting the programmed cell death-1 receptor, as well as with the advent of new generation tyrosine-kinase receptor inhibitors. This article will review the new therapeutic options available for the treatment of advanced RCC, as well as the future potential molecular targets that are currently being investigated.
登录
查看更多内容
DOI：
10.1056/nejmoa1510016
发表时间：
2015-11-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Choueiri TK;Escudier B;Powles T;Mainwaring PN;Rini BI;Donskov F;Hammers H;Hutson TE;Lee JL;Peltola K;Roth BJ;Bjarnason GA;Géczi L;Keam B;Maroto P;Heng DY;Schmidinger M;Kantoff PW;Borgman-Hagey A;Hessel C;Scheffold C;Schwab GM;Tannir NM;Motzer RJ;METEOR Investigators
通讯作者：
METEOR Investigators
影响因子：
168.9
作者：
Escudier, Bernard;Pluzanska, Anna;Moore, Nicola
通讯作者：
Moore, Nicola
影响因子：
158.5
作者：
Kantoff, Philip W.;Higano, Celestia S.;Young, J.
通讯作者：
Young, J.
影响因子：
5
作者：
Kang, Myoung Jae;Kim, Kyoung Min;Jang, Kyu Yun
通讯作者：
Jang, Kyu Yun
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM